Hepatitis B infection is a leading cause of liver disease with over 240 million chronic carriers. Current protective vaccines elicit protective immune responses in up to 95% of healthy adults but are poorly immunogenic in immunocompromised individuals and there are currently no effective therapeutic vaccines available. CD180, also known as radioprotective 105 kDa protein (RP105), is a Toll-like receptor (TLR), type-1 glycoprotein expressed on antigen presenting cells (APC) in complex with the accessory molecule MD-1. Engagement of antibodies with CD180 promotes proliferation of B cells, and targeting of antigen to CD180 has been shown to enhance antigen-specific B cell and T cell responses. Aims: The aim of this project is to clone the duck CD180 and MD-1 cDNA and to characterize the expressed protein.
